Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
167.26
-2.10 (-1.24%)
Nov 22, 2024, 4:00 PM EST - Market closed
Natera Revenue
Natera had revenue of $439.76M in the quarter ending September 30, 2024, with 63.90% growth. This brings the company's revenue in the last twelve months to $1.53B, up 54.94% year-over-year. In the year 2023, Natera had annual revenue of $1.08B with 31.99% growth.
Revenue (ttm)
$1.53B
Revenue Growth
+54.94%
P/S Ratio
13.29
Revenue / Employee
$465,216
Employees
3,293
Market Cap
22.08B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.08B | 262.35M | 31.99% |
Dec 31, 2022 | 820.22M | 194.74M | 31.13% |
Dec 31, 2021 | 625.49M | 234.48M | 59.97% |
Dec 31, 2020 | 391.01M | 88.68M | 29.33% |
Dec 31, 2019 | 302.33M | 44.67M | 17.34% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Koninklijke Philips | 20.12B |
Labcorp Holdings | 12.71B |
Biogen | 9.61B |
Zimmer Biomet Holdings | 7.60B |
STERIS | 5.33B |
Illumina | 4.39B |
The Cooper Companies | 3.80B |
BeiGene | 3.35B |
NTRA News
- 1 day ago - Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM - Business Wire
- 10 days ago - Natera, Inc. (NTRA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Natera Reports Third Quarter 2024 Financial Results - Business Wire
- 11 days ago - Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer - Business Wire
- 15 days ago - Natera to Participate in Upcoming Investor Conferences - Business Wire
- 22 days ago - Natera to Report its Third Quarter 2024 Results on November 12, 2024 - Business Wire
- 23 days ago - Cigna Turns $739 Million Profit Despite $1 Billion Loss On VillageMD - Forbes
- 4 weeks ago - Natera to Present New Renasight Data at ASN Kidney Week 2024 - Business Wire